U.S. Congress - S.2210 Medical Innovation Prize Act of 2007
S.2210 - Medical Innovation Prize Act of 2007
A bill to provide incentives for investment in research and development for new medicines, to enhance access to new medicines, and for other purposes. view all titles (2)
All Bill Titles
- Official: A bill to provide incentives for investment in research and development for new medicines, to enhance access to new medicines, and for other purposes. as introduced.
- Short: Medical Innovation Prize Act of 2007 as introduced.
This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.
Bill's Views
- Today: 3
- Past Seven Days: 22
- All-Time: 2,652
|
|
|
|
|
|
|
|
Official Summary
10/19/2007--Introduced.Medical Innovation Prize Act of 2007 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use in interstate commerce a drug, a biological product, or a drug or biological product manufacturing process, including the exclusiveOfficial Summary
10/19/2007--Introduced.Medical Innovation Prize Act of 2007 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use in interstate commerce a drug, a biological product, or a drug or biological product manufacturing process, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents under the Federal Food, Drug, and Cosmetic Act, notwithstanding provisions of that Act and other specified laws. Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process. Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent. Directs the Board to consider:
(1) the number of patients who benefited from the drug, including non-U.S. patients;
(2) the incremental therapeutic benefit of the drug to treat the same disease or condition, except that the Board shall provide for cases where drugs, biological products, or manufacturing processes are developed at roughly the same time so that the comparison is to products that were not recently developed;
(3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and
(4) the improved efficiency of manufacturing processes for drugs or biological processes. Allows the Board to award prize payments for no more than ten years. Allocates certain minimum payments from the Fund for priority research and development.
Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and in addressing society's global medical needs.
...Read the Rest
Recent News Coverage
Hmmmm, no news coverage found for this bill at this time. This means that this this bill has not yet been mentioned on a publicly-searchable news website by either its official number (for example, "H.R. 3200") or title (for example, "America's Affordable Health Choices Act of 2009"). As soon as that changes, our daily automated search across the Web will catch it and include it here. If this bill is of interest to you, you can write a letter to the editor referring to this bill by name, and if your letter is published on the Web, a link back your letter will appear here within about one day. Or, if you know of a news article about this bill to display here, email us the web address of this page and the web address of your suggested news article: Our editorial team will post relevant links as quickly as possible. Thanks for helping to build public knowledge about Congress.
Recent Blog Coverage
View All (13)
|
View Top Rated
HIF on the Sanders prize fund bill - Knowledge Ecology Notes
In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sandersâ proposal for the Medical Innovation Prize Fund. ...
The Health Impact Fund and product monopolies
... and which were incorporated in the two Sanders bills (HR 417, 109th Congress, S.2210, 110th Congress) and a variety of other proposals, including those most recently advanced by Barbados and Bolivia in the WHO discussions. ...
John McCainâs Prize System: $300 Million for Battery Power
Now Pending S.2210 is the "Medical Innovation Prize Act of 2007." The act would attempt to "de-couple" the reward for pharmaceutical product research from the market price of the product. Unlike more traditional prizes, this one would .
Users tracking S.2210 (1) are also tracking:
| Bills | People |
|---|---|
Users supporting S.2210 (3) are also:
| Supporting Bill | Supporting Senator | Supporting Representative |
|---|---|---|
| Opposing Bill | Opposing Senator | Opposing Representative |
|---|---|---|
Vote on This Bill
-
Share This Bill
More Share via Email
